Celldex Therapeutics, Inc. (CLDX) Current Ratio
- Current ratio · latest quarter: Value 11.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 11.82× | Current assets / current liabilities. $724.93M ÷ $61.33M ≈ 11.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 724.93M USD | Assets, Current |
| Current obligations | 61.33M USD | Liabilities, Current |
| Cash and equivalents | 47.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 670.13M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 14.68M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $724.93M | $61.33M | $47.45M | $670.13M | (m) | (m) | $14.68M | (m) | 11.82× |
| 2026-03-31 | $459.22M | $51.47M | $35.73M | $415.73M | (m) | (m) | $10.36M | (m) | 8.92× |
| 2025-12-31 | $534.66M | $50.99M | $28.87M | $489.70M | (m) | (m) | $1.18M | (m) | 10.49× |
| 2025-09-30 | $604.34M | $46.47M | $36.04M | $547.19M | (m) | (m) | $4.27M | (m) | 13.01× |
| 2025-06-30 | $648.40M | $32.96M | $23.04M | $607.29M | (m) | (m) | $2.07M | (m) | 19.67× |
| 2025-03-31 | $693.76M | $32.02M | $17.14M | $656.15M | (m) | (m) | $3.41M | (m) | 21.67× |
| 2024-12-31 | $747.16M | $39.50M | $28.36M | $696.92M | (m) | (m) | $3.27M | (m) | 18.91× |
| 2024-09-30 | $778.84M | $32.09M | $36.40M | $719.60M | (m) | (m) | $1.11M | (m) | 24.27× |
| 2024-06-30 | $811.98M | $27.66M | $42.74M | $759.58M | (m) | (m) | $3.80M | (m) | 29.36× |
| 2024-03-31 | $835.32M | $26.29M | $115.08M | $708.77M | (m) | (m) | $3.23M | (m) | 31.77× |
| 2023-12-31 | $431.69M | $31.13M | $34.81M | $388.78M | (m) | (m) | $3.49M | (m) | 13.87× |
| 2023-09-30 | $245.93M | $27.84M | $21.13M | $214.21M | (m) | (m) | $3.59M | (m) | 8.84× |
| 2023-06-30 | $264.82M | $15.65M | $28.22M | $224.47M | (m) | (m) | $881.00K | (m) | 16.93× |
| 2023-03-31 | $289.60M | $15.22M | $54.12M | $224.26M | (m) | (m) | $3.37M | (m) | 19.03× |
| 2022-12-31 | $317.69M | $18.61M | $29.43M | $275.52M | (m) | (m) | $3.34M | (m) | 17.07× |
| 2022-09-30 | $334.60M | $16.29M | $18.58M | $304.89M | (m) | (m) | $2.27M | (m) | 20.54× |
| 2022-06-30 | $367.98M | $29.95M | $28.40M | $328.42M | (m) | (m) | $902.00K | (m) | 12.29× |
| 2022-03-31 | $390.70M | $14.56M | $25.29M | $355.18M | (m) | (m) | $1.02M | (m) | 26.83× |
| 2021-12-31 | $410.84M | $16.53M | $39.14M | $369.11M | (m) | (m) | $1.23M | (m) | 24.86× |
| 2021-09-30 | $426.56M | $14.18M | $72.18M | $350.90M | (m) | (m) | $836.00K | (m) | 30.09× |
| 2021-06-30 | $167.61M | $14.49M | $43.45M | $120.59M | (m) | (m) | $685.00K | (m) | 11.57× |
| 2021-03-31 | $181.50M | $16.98M | $69.31M | $106.77M | (m) | (m) | $997.00K | (m) | 10.69× |
| 2020-12-31 | $197.84M | $14.21M | $43.84M | $150.59M | (m) | (m) | $1.05M | (m) | 13.93× |
| 2020-09-30 | $202.93M | $12.20M | $18.15M | $181.44M | (m) | (m) | $568.00K | (m) | 16.63× |
| 2020-06-30 | $208.99M | $10.84M | $68.03M | $138.89M | (m) | (m) | $950.00K | (m) | 19.28× |
| 2020-03-31 | $55.92M | $10.93M | $22.72M | $31.00M | (m) | (m) | $1.61M | (m) | 5.12× |
| 2019-12-31 | $66.70M | $11.64M | $11.23M | $53.15M | (m) | (m) | $1.17M | (m) | 5.73× |
| 2019-09-30 | $75.10M | $11.89M | $16.59M | $56.33M | (m) | (m) | $666.00K | (m) | 6.32× |
| 2019-06-30 | $84.36M | $11.51M | $19.74M | $61.60M | (m) | (m) | $1.02M | (m) | 7.33× |
| 2019-03-31 | $88.85M | $11.99M | $31.53M | $53.53M | (m) | (m) | $1.10M | (m) | 7.41× |
| 2018-12-31 | $99.08M | $12.60M | $24.31M | $69.71M | (m) | (m) | $1.07M | (m) | 7.86× |
| 2018-09-30 | $110.97M | $16.85M | $32.82M | $72.80M | (m) | (m) | $2.31M | (m) | 6.59× |
| 2018-06-30 | $120.28M | $19.98M | $43.89M | $70.11M | (m) | (m) | $2.94M | (m) | 6.02× |
| 2018-03-31 | $130.97M | $24.01M | $39.82M | $83.42M | (m) | (m) | $508.00K | (m) | 5.45× |
| 2017-12-31 | $144.76M | $27.74M | $40.29M | $99.14M | (m) | (m) | $1.72M | (m) | 5.22× |
| 2017-09-30 | $147.32M | $24.91M | $54.73M | $85.80M | (m) | (m) | $1.28M | (m) | 5.91× |
| 2017-06-30 | $160.05M | $28.79M | $66.16M | $87.82M | (m) | (m) | $1.98M | (m) | 5.56× |
| 2017-03-31 | $173.46M | $27.02M | $42.50M | $124.53M | (m) | (m) | $2.66M | (m) | 6.42× |
| 2016-12-31 | $195.57M | $35.22M | $42.46M | $147.31M | (m) | (m) | $1.74M | (m) | 5.55× |
| 2016-09-30 | $209.71M | $18.63M | $31.74M | $171.50M | (m) | (m) | $1.02M | (m) | 11.26× |
| 2016-06-30 | $228.78M | $20.00M | $32.48M | $187.65M | (m) | (m) | $706.00K | (m) | 11.44× |
| 2016-03-31 | $260.95M | $25.31M | $63.02M | $190.99M | (m) | (m) | $2.64M | (m) | 10.31× |
| 2015-12-31 | $294.94M | $30.24M | $72.11M | $217.78M | (m) | (m) | $1.51M | (m) | 9.75× |
| 2015-09-30 | $309.26M | $23.64M | $66.79M | $237.82M | (m) | (m) | $1.22M | (m) | 13.08× |
| 2015-06-30 | $339.54M | $26.69M | $81.58M | $252.41M | (m) | (m) | $2.02M | (m) | 12.72× |
| 2015-03-31 | $364.13M | $21.15M | $122.17M | $237.60M | (m) | (m) | $3.07M | (m) | 17.22× |
| 2014-12-31 | $204.99M | $24.49M | $28.02M | $173.02M | (m) | (m) | $2.60M | (m) | 8.37× |
| 2014-09-30 | $229.82M | $21.61M | $32.52M | $191.55M | (m) | (m) | $1.72M | (m) | 10.63× |
| 2014-06-30 | $255.60M | $21.20M | $40.80M | $211.57M | (m) | (m) | $1.19M | (m) | 12.06× |
| 2014-03-31 | $276.82M | $19.51M | $56.90M | $217.32M | (m) | (m) | $3.41M | (m) | 14.19× |
| 2013-12-31 | $305.19M | $20.35M | $169.40M | $133.58M | (m) | (m) | $2.24M | (m) | 15.00× |
| 2013-09-30 | $139.95M | $16.80M | $14.63M | $121.96M | (m) | (m) | $1.98M | (m) | 8.33× |
| 2013-06-30 | $156.43M | $12.50M | $25.90M | $129.08M | (m) | (m) | $2.07M | (m) | 12.51× |
| 2013-03-31 | $184.45M | $18.33M | $75.63M | $106.75M | (m) | (m) | $2.45M | (m) | 10.06× |
| 2012-12-31 | $85.11M | $17.68M | $24.90M | $59.06M | (m) | (m) | $745.00K | (m) | 4.81× |
| 2012-09-30 | $78.81M | $15.13M | $23.19M | $54.43M | (m) | (m) | $1.28M | (m) | 5.21× |
| 2012-06-30 | $80.40M | $12.58M | $18.56M | $60.11M | (m) | (m) | $395.00K | (m) | 6.39× |
| 2012-03-31 | $94.24M | $12.55M | $22.75M | $69.37M | (m) | (m) | $535.00K | (m) | 7.51× |
| 2011-12-31 | $54.68M | $14.30M | $11.90M | $41.41M | (m) | (m) | $935.00K | (m) | 3.82× |
| 2011-09-30 | $64.38M | $10.78M | $13.10M | $49.68M | (m) | (m) | $457.00K | (m) | 5.97× |
| 2011-06-30 | $73.29M | $10.41M | $10.83M | $60.41M | (m) | (m) | $514.00K | (m) | 7.04× |
| 2010-12-31 | $62.95M | $20.21M | $21.29M | $39.81M | (m) | (m) | $931.00K | (m) | 3.11× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |